Radiation proctitis
ICD-10 K62.7 · ICD-11 DB33.42

Treatment of Grade 1 Chronic Radiation Proctitis

Chronic radiation proctitis (CRP) is a recognised late complication of pelvic radiotherapy. Grading CRP is a necessary first step — the grade directly determines the appropriate level and type of intervention. In Grade 1 CRP, the primary clinical objective is control of rectal bleeding.

Clinical Scenario

The patient has established chronic radiation proctitis, formally assessed as Grade 1. The working goal is to achieve cessation or a substantial reduction in rectal bleeding — hemostasis is the defined endpoint for this grade.

Treatment Approach — Partial Overview

Management in this setting centres on targeted interventions directed at the rectal mucosa — including topical chemical approaches and endoscopic energy-based techniques. Preparatory measures are required before certain modalities are employed. The full protocol, including selection criteria and procedural sequencing, is available via the link below.

Treatment Goal

Cessation or substantial decrease in rectal bleeding (hemostasis).

References

DOI: 10.5946/ce.2020.288

Chronic radiation proctitis (CRP). Establish the grade of CRP. Grade 1.

Formalin (formaldehyde 4%–10%) has been used in treating chronic RP over the past few decades.

A formalin-soaked gauze can be applied directly to the mucosa via rigid proctoscopy under light sedation, and it brings about chemical cauterization of the ulcers and telangiectasias, thereby achieving hemostasis.

ASCRS recommends using argon beam plasma coagulation (APC) as it is a safe and effective modality for treating chronic RP.

A complete bowel lavage should be performed prior to APC therapy to evacuate combustible gas and prevent bowel explosion with perforation.

Neodymium-doped yttrium aluminum garnet laser can also be used to coagulate the bleeding vessel in these patients.

The literature reports the need for a median of two APC sessions (range: 1–5 sessions) to control rectal hemorrhage, thereby resulting in cessation or a substantial decrease in bleeding in 79%–100% of the patients.

View source ↗